Sarepta Therapeutics Inc. (SRPT)

84.84
2.20 2.50
NASDAQ : Health Technology
Prev Close 87.02
Open 87.41
Day Low/High 83.91 / 88.15
52 Wk Low/High 83.62 / 165.87
Volume 1.55M
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 74.34M
Market Cap 6.54B
EPS -5.50
Div & Yield N.A. (N.A)
I Am One of the Underinvested Bulls Right Now

I Am One of the Underinvested Bulls Right Now

It's challenging to put cash to work but I'll keep digging.

Jim Cramer: Sarepta Could Be a Takeover Target, but I'm Not Buying Shares

Jim Cramer: Sarepta Could Be a Takeover Target, but I'm Not Buying Shares

Shares of drug-maker Sarepta are higher Tuesday on the back of an upgrade from RBC, but Jim Cramer says he's not adding shares to his portfolio.

Sarepta Therapeutics Shares Buoyed by RBC Upgrade

Sarepta Therapeutics Shares Buoyed by RBC Upgrade

Analysts say the Duchenne muscular-dystrophy treatment could be a "major game changer" for Sarepta Therapeutics.

These Biotech Names Are on My Radar

These Biotech Names Are on My Radar

But I'm expecting that things will slow into the Fed news.

Morning Movers: CHK, WFC, SRPT

Morning Movers: CHK, WFC, SRPT

Billionaire activist investor Carl Icahn helped pull down Chesapeake Energy by unveiling a substantial selloff.

Sarepta upgraded at Jefferies

Market Slows Down, Waiting for Wednesday

Market Slows Down, Waiting for Wednesday

Concerns are starting to pop up that maybe the Fed statement will have a hawkish tone.

Trending Tickers: SRPT, WFC, GM, LMT, UPS

Trending Tickers: SRPT, WFC, GM, LMT, UPS

A drug approval sends Sarepta skyrocketing, while analysts' actions dominate other market movers.

Midday Report: Sarepta Soars on FDA Approval; U.S. Stocks Climb on Oil Rally

Midday Report: Sarepta Soars on FDA Approval; U.S. Stocks Climb on Oil Rally

Stocks hold higher through the morning session as crude oil extends earlier gains.

Seeing the Same Old Patterns Ahead of Fed News

Seeing the Same Old Patterns Ahead of Fed News

Buyers expect a dovish Fed and are still trying to put money to work.

Sarepta Shares Jump as FDA Official Departs; Jim Cramer Says It's Good News

Sarepta Shares Jump as FDA Official Departs; Jim Cramer Says It's Good News

Jim Cramer is watching Sarepta shares after an FDA official critical of the drug steps down.

Fear of Being Left Out Is Lifting Indices

Fear of Being Left Out Is Lifting Indices

The overall technical condition of the indices remains negative.

Who Needs a Revenue Stream?

Who Needs a Revenue Stream?

Though highly speculative, Sarepta Therapeutics could be a short-term play.

Shares of Sarepta Plunge on FDA Categorization of Duchenne Drug

Shares of Sarepta Plunge on FDA Categorization of Duchenne Drug

Shares of Sarepta plunged 27 percent on Thursday after the Food and Drug Administration finalized procedures for expanding access to unapproved drugs.

Trending Tickers: SIG, SRPT, QLIK, WMT

Although markets are flat, Sarepta and Signet have been big movers.

Trending Tickers: SRPT, BABA, CSC, CHK, C

Banks and Biotech are up as the stock market continues to gain momentum.

Jim Cramer Still Likes Home Depot, Kroger, But Tough to Buy Them Now

Jim Cramer Still Likes Home Depot, Kroger, But Tough to Buy Them Now

Jim Cramer talks oil, Citigroup, burger joints and biotechs.

Stock Futures Move Higher; Cramer Is Watching GameStop 3Q Earnings

Also, Pfizer-Allergan deal clears another hurdle.

An Old-Fashioned Market Melt-Up

Stay open-minded and expect the unexpected.

Sarepta upgraded at Wedbush

Sarepta upgraded at Piper

Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece

Cramer Worried About Airline Overcapacity, Hints at Surprise McDonald's Piece

Jim Cramer likes Soutwest (LUV), isn't a fan of Sarepta Therapeutics (SRPT) and will soon have a 'surprise' piece on McDonald's (MCD).

Market Wrap: Trading in Narrow Range Nets Mixed Results

Housing stocks rally on favorable news.

The Trader Daily

We're transitioning toward more balanced markets.

Out on a Positive Note

The market was in a holiday mood.

Not Dead Yet

Not Dead Yet

Two names down in the dumps but showing a little life.

Searching for Clarity

This market is messy and uneven.

Sarepta downgraded at Piper

Caveat Emptor

Sarepta Therapeutics is the disaster du jour. The disaster du jour, a stock often mentioned in our comments section (Jack's favorite equity) and on message boards, is Sarepta Therapeutics (SRPT).